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Since 2013, the H7N9 avian influenza virus is considered a threat to global public health. The development of 
the H7N9 avian influenza vaccine is one of the most effective strategies to prevent influenza pandemics. Virus-
like particles (VLPs) influenza vaccines is non-infectious viral structural proteins. Not only to retain the ability to 
produce neutralizing antibodies against to viral surface protein, but also safer than the conventional inactivated 
vaccines. In our previous study, we successfully expressed three structural proteins, hemagglutinin (HA), 
neuraminidase (NA) and matrix (M1) from influenza A / Taiwan / 1/2013 (H7N9) of the VLP in insect cells. In this 
study, we present a downstream purification method for the VLP platform. The purification process involves 
microfiltration, chromatography (using ion exchange, affinity and gel filtration combinations), concentration, 
diafiltration and sterile filtration steps. In this study, 600 ml of the harvest from the baculovirus expression 
system was used. The characteristics of VLP volume were examined by HA assay, SDS-PAGE and negative 
staining transmission electron microscopy (TEM). The overall recovery of HA protein was approximately 38%. In 
the evaluation of immunized mouse, such virus particles have been shown the HI titer >256. This study 
demonstrated the chromatographic-based purification process can provide an effective VLP vaccine production 
for the preparation of the H7N9 influenza pandemic. 
 
 
